Literature DB >> 25093262

Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Rafael Scaf de Molon1, Simon Cheong2, Olga Bezouglaia3, Sarah M Dry4, Flavia Pirih5, Joni Augusto Cirelli6, Tara L Aghaloo7, Sotirios Tetradis8.   

Abstract

Although osteonecrosis of the jaws (ONJ), a serious complication of antiresorptive medications, was reported a decade ago, the exact mechanisms of disease pathophysiology remain elusive. ONJ-like lesions can be induced in animals after antiresorptive treatment and experimental interventions such as tooth extraction or periapical or periodontal disease. However, experimental induction and manipulation of disease progression does not always reflect clinical reality. Interestingly, naturally occurring maxillofacial abscesses, inducing aggressive inflammation of the peri-radicular mucosa with significant osteolysis and alveolar bone expansion, have been reported in mice. Here, we aimed to explore whether osteonecrotic lesions would develop in areas of maxillary peri-radicular infections, in mice on antiresorptive medications with distinct pharmacologic action, thus establishing a novel ONJ animal model. Mice were treated with RANK-Fc or OPG-Fc that bind to RANKL or with the potent bisphosphonate zoledronic acid (ZA). Maxillae were assessed radiographically and histologically. μCT imaging of vehicle mice revealed several maxillae with altered alveolar bone morphology, significant ridge expansion and large lytic areas. However, in RANK-Fc, OPG-Fc and ZA treated animals the extent of bone loss was significantly less, but exuberant bone deposition was noted at the ridge periphery. BV and BV/TV were increased in the diseased site of antiresorptive vs. veh animals. Histologically, extensive inflammation, bone resorption and marginal gingival epithelium migration were seen in the diseased site of vehicle animals. Rank-Fc, OPG-Fc and ZA reduced alveolar bone loss, increased periosteal bone formation, and induced areas of osteonecrosis, and bone exposure that in many animals covered significant part of the alveolar bone. Collectively, our data demonstrate ONJ-like lesions at sites of maxillary peri-radicular infection, indistinguishable in mice treated with RAKL inhibitors vs. zoledronate. This novel mouse model of spontaneous ONJ supports a central role of osteoclast inhibition and infection/inflammation in ONJ pathogenesis and validates and complements existing animal models employing experimental interventions.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alveolar bone; Antiresorptives; Bisphosphonates; ONJ; Osteoclasts; Osteonecrosis of the jaw

Mesh:

Substances:

Year:  2014        PMID: 25093262      PMCID: PMC4476062          DOI: 10.1016/j.bone.2014.07.027

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  50 in total

1.  Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.

Authors:  J Ignacio Aguirre; Mohammed P Akhter; Donald B Kimmel; Jennifer E Pingel; Alyssa Williams; Marda Jorgensen; Lakshmyya Kesavalu; Thomas J Wronski
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741

2.  Extraction socket healing in rats treated with bisphosphonate: animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients.

Authors:  Mehmet Ali-Erdem; Abdulkadir Burak-Cankaya; Sabri Cemil-Isler; Sabit Demircan; Merva Soluk; Cetin Kasapoglu; Cuneyt Korhan-Oral
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2011-11-01

3.  Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws.

Authors:  Pía López-Jornet; Fabio Camacho-Alonso; Ascensión Martínez-Canovas; Francisco Molina-Miñano; Francisco Gómez-García; Vicente Vicente-Ortega
Journal:  J Oral Maxillofac Surg       Date:  2011-07-27       Impact factor: 1.895

Review 4.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

5.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

Authors:  Matthew R Smith; Fred Saad; Robert Coleman; Neal Shore; Karim Fizazi; Bertrand Tombal; Kurt Miller; Paul Sieber; Lawrence Karsh; Ronaldo Damião; Teuvo L Tammela; Blair Egerdie; Hendrik Van Poppel; Joseph Chin; Juan Morote; Francisco Gómez-Veiga; Tomasz Borkowski; Zhishen Ye; Amy Kupic; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-11-15       Impact factor: 79.321

6.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

Review 7.  Antiresorptives and osteonecrosis of the jaw.

Authors:  Junro Yamashita; Laurie K McCauley
Journal:  J Evid Based Dent Pract       Date:  2012-09       Impact factor: 5.267

8.  Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Authors:  Allan Lipton; Karim Fizazi; Alison T Stopeck; David H Henry; Janet E Brown; Denise A Yardley; Gary E Richardson; Salvatore Siena; Pablo Maroto; Michael Clemens; Boris Bilynskyy; Veena Charu; Philippe Beuzeboc; Michael Rader; Maria Viniegra; Fred Saad; Chunlei Ke; Ada Braun; Susie Jun
Journal:  Eur J Cancer       Date:  2012-09-10       Impact factor: 9.162

9.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

Review 10.  Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.

Authors:  George Dranitsaris; Eleftheria Hatzimichael
Journal:  Support Care Cancer       Date:  2012-04-27       Impact factor: 3.603

View more
  26 in total

1.  OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.

Authors:  Rafael Scaf de Molon; Hiroaki Shimamoto; Olga Bezouglaia; Flavia Q Pirih; Sarah M Dry; Paul Kostenuik; Rogely W Boyce; Denise Dwyer; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2015-05-27       Impact factor: 6.741

2.  Zoledronate Impairs Socket Healing after Extraction of Teeth with Experimental Periodontitis.

Authors:  A Soundia; D Hadaya; N Esfandi; I Gkouveris; R Christensen; S M Dry; O Bezouglaia; F Pirih; N Nikitakis; T Aghaloo; S Tetradis
Journal:  J Dent Res       Date:  2017-09-27       Impact factor: 6.116

3.  Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris).

Authors:  J G Messer; E J Castillo; A M Abraham; J M Jiron; R Israel; J F Yarrow; S Thomas; M C Reynolds; R D Wnek; M Jorgensen; N Wanionok; C Van Poznak; I Bhattacharyya; D B Kimmel; J I Aguirre
Journal:  Bone       Date:  2019-11-07       Impact factor: 4.398

4.  Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease.

Authors:  Akrivoula Soundia; Danny Hadaya; Navid Esfandi; Rafael Scaf de Molon; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2016-06-18       Impact factor: 4.398

Review 5.  Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.

Authors:  Jenny A F Vermeer; Greetje A P Renders; Vincent Everts
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

6.  Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro.

Authors:  Kenichi Ogata; Wataru Katagiri; Hideharu Hibi
Journal:  Clin Oral Investig       Date:  2016-10-29       Impact factor: 3.573

Review 7.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

8.  Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.

Authors:  Rafael Scaf de Molon; Chingyun Hsu; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Akrivoula Soundia; Fernando Queiroz Cunha; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2016-05-04       Impact factor: 6.741

9.  Long-term evaluation of oral gavage with periodontopathogens or ligature induction of experimental periodontal disease in mice.

Authors:  Rafael Scaf de Molon; Vinicius Ibiapina Mascarenhas; Erica Dorigatti de Avila; Livia Sertori Finoti; Gustavo Boze Toffoli; Denise Madalena Palomari Spolidorio; Raquel Mantuaneli Scarel-Caminaga; Sotirios Tetradis; Joni Augusto Cirelli
Journal:  Clin Oral Investig       Date:  2015-09-28       Impact factor: 3.573

Review 10.  Pathophysiology of Osteonecrosis of the Jaws.

Authors:  Tara Aghaloo; Renna Hazboun; Sotirios Tetradis
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2015-09-26       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.